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Abstract
Aim: To systematically review the available literature on the prevalence and clinical characteristics of headache in patients
with Tourette syndrome (TS), a neurodevelopmental condition characterized by the chronic presence of motor and vocal
tics.
Design:We conducted a systematic literature review of original studies using three clinical databases (Medline, EMBASE
and PsycInfo), according to the standards outlined in the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines. Outcome measures included both tic severity and tic frequency.
Results: Our systematic literature review identified six studies on the prevalence and characteristics of headache in
patients with TS (data on paediatric patients were available from five studies and data on adult patients from four studies).
The proportion of patients with TS who had a diagnosis of headache ranged from 29% to 62%. Migraine was the most
commonly investigated headache disorder in this patient population. The findings of the reviewed studies showed that the
prevalence of migraine in patients with TS ranges between 13% and 43% and is significantly higher compared to the two
control groups (p < 0.05).
Discussion: The prevalence of headache in patients with TS could be higher than in the general population, with the most
reliable data being available for migraine. Overall, the literature on the prevalence and characteristics of headache in TS is
sparse and highly heterogeneous. Further research on the prevalence and clinical correlates of migraine, tension-type
headache and other types of headache in patients with TS across the lifespan is needed to inform clinical practice aimed at
improving health-related quality of life in patients with tics.
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Introduction
Tourette syndrome (TS) is a complex neurodevelopmental
disorder characterized by the chronic presence of multiple
motor tics plus at least one vocal tic since childhood or
adolescence.1,2 Tics are defined as sudden, involuntary,
repetitive, non-rhythmic movements and vocalizations and
are characteristically preceded by sensory experiences
(‘premonitory urges’).3,4 It is estimated that 0.3–1% of
school-age children fulfil the diagnostic criteria for TS,
with differing degrees of severity.5,6 The majority of
patients with TS present with co-morbid conditions, includ-
ing obsessive–compulsive disorder (OCD) and attention-
deficit and hyperactivity disorder (ADHD), as well as
frequent affective symptoms and impulsivity.7 Over the last
few decades, there has been growing interest in co-morbid
psychiatric disorders (especially tic-related OCD and
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ADHD), in consideration of their impact on patients’
health-related quality of life across the lifespan.7–9 Rela-
tively little is known about the neurological co-morbidities
of TS, despite reports of neurological soft signs10 and
increased risk for common neurological conditions such
as epilepsy.11 Moreover, pain is increasingly being recog-
nized as a prominent feature of TS, presumably of multi-
factorial origin.12
The association between TS and headache has been
investigated in a number of observational studies, suggest-
ing an increased prevalence of headache in patients with
TS. However, to date, there has been no systematic review
summarizing and critically appraising these findings. Spe-
cifically, little is known about the prevalence of different
types of headache in patients with TS, as well as the clinical
correlates of headache in this patient population. A better
understanding of the relationship between TS and headache
could shed some light on the possible pathophysiological
mechanisms leading to the development of both tics and
specific headache types. Moreover, evidence-based knowl-
edge on this aspect of TS would enable clinicians to
improve diagnostic and therapeutic strategies for patients.
We, therefore, set out to conduct a systematic literature
review on the prevalence of the main different types of
headache and their clinical correlates in patients with TS.
Methods
This systematic literature review was conducted in accor-
dance to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines,13 used in conjunc-
tion with the Explanation and Elaboration document.14 We
included in our review all studies on the prevalence and
clinical characteristics of headache in patients with a for-
mal diagnosis of TS according to the Diagnostic and Sta-
tistical Manual for Mental Disorders (DSM) criteria.1 Only
studies in which headache was diagnosed using criteria
outlined by the International Classification of Headache
Disorders (ICHD) or criteria matching those set by the
ICHD (in studies that did not explicitly mention ICHD
criteria) were considered for inclusion.15 Case series and
case single reports were excluded from this review, as well
as study abstracts without the availability of full texts.
The searches were conducted on three clinical data-
bases: Medline, EMBASE and PsycInfo. The search terms
were as follows: ‘Tourette*’ OR ‘Tic*’ AND ‘Headache*’
OR ‘Migrain*’. For comprehensiveness, the reference lists
of eligible articles were also screened to identify any rele-
vant articles. Google Scholar was used to search for the
grey literature. Since a few of the reviewed studies were
published in the same scientific journals, the contents of
relevant journals, including Cephalalgia, Headache, Move-
ment Disorders, Journal of Neurology Neurosurgery and
Psychiatry and Journal of Neuropsychiatry and Clinical
Neurosciences, were manually searched for any further
articles on the reviewed topic. We did not limit our search
to articles published in English language, and there were no
chronological, geographic or demographic limitations to
the inclusion of studies. Both qualitative and quantitative
study designs were included for review. The Crowe Critical
Appraisal Tool (CCAT) was used to assess the quality of
the selected studies, and any studies scoring less than 30%
were excluded from the review.16,17
Results
Our systematic literature search yielded a total of 1144
articles, after removal of duplicates. A manual search of
reference lists for relevant articles yielded a further 12
articles, for a total of 1156 articles. Of these, 44 were
considered relevant to the review and their full texts were
inspected, after 8 studies were excluded because their full
texts were not available. A total of 10 articles that looked at
headache prevalence in TS, but did not include ICHD cri-
teria or criteria consistent with ICHD standard as part of
their study, were excluded from the present review. Seven
articles (corresponding to six independent studies) met all
the inclusion criteria and were included in the present
review (Figure 1).18–24
The six independent studies, summarized in Table 1,
involved a total of 465 patients with TS (average sample
size 78 patients; range 21–140 patients).
DSM-validated criteria for the diagnosis of TS were used
in four studies,18–20,22,24 the diagnostic criteria developed by
the Tourette Syndrome Classification Study Group were
used in one study,21 and formal diagnosis of TS with no
explicit reference to published criteria was established in
one study.23 The ICHD criteria for the diagnosis of headache
were used in four of the reviewed studies,21–24 and criteria
for the diagnosis of headache that were consistent with the
ICHD standards were used in two studies published before
the introduction of the ICHD criteria.18–20 Data on paediatric
patients were available from five studies18–22,24 and data on
adult patients from four studies.20,21,23,24 Table 2 details the
quality assessment of the reviewed studies on headache in
patients with TS, with individual CCAT scores.
Three of the included studies reported prevalence fig-
ures for overall headache, migraine and tension-type head-
ache in patients with TS.22–24 The remaining three studies
focused on the prevalence of migraine only.18–21
The prevalence of overall headache in patients with TS
ranged from 28.6% to 61.9%, whereas the prevalence of
tension-type headache ranged from 7.3% to 35.5%.
Migraine was found to be the most researched headache
disorder with regard to its association with TS, as all of the
included studies investigated the prevalence of this head-
ache disorder in clinical samples of patients with TS: the
reported prevalence figures ranged from 12.9% to 43.3%
(Table 3).
One study found that migraine was significantly more
frequent in children with TS compared to adults with TS,
whereas the prevalence of tension-type headache followed
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the opposite pattern.24 One study reported the prevalence of
other types of headaches to be 11.0%.22
The presence of co-morbid disorders was not found to be
associated with significantly higher rates of headache in
patients with TS.22,23 Although the presence of attention-
deficit and hyperactivity symptoms and obsessive–compul-
sive symptoms was not significantly associated with higher
rates of migraine,21 co-morbid sleep-related behavioural
symptoms and abnormal electroencephalographic (EEG)
findings were associated with significantly higher rates of
migraine in patients with TS.19 Finally, the results of one
study showed that adults with TS and co-morbid headache
consistently presented with higher tic severity and poorer
quality of life compared to children with TS and co-morbid
headache (p ¼ 0.01).24
Discussion
We conducted the first systematic literature review on the
prevalence and clinical correlates of headache in patients
with TS. Our search yielded 6 studies, involving a total of
465 patients with TS.18–24 The three studies that assessed the
overall prevalence of headache in patients with TS found
that headache is a commonly reported condition in this
patient population, with prevalence figures ranging from
28.6% to 61.9%.22–24 Of note, the reported prevalence of
headache in adults with TS (range 48.4–61.9%)23,24 was
higher than the prevalence of headache in the general adult
population as reported in a 2007 documentation of headache
prevalence and disability worldwide.25 However, based on
the World Health Organization’s atlas of headache disorders
published in 2011,26 the 1-year prevalence of headache glob-
ally for adults age 18–65 ranged from 21.6% in African
countries to 78.8% in the Eastern Mediterranean (46.5% in
the Americas): a range of prevalence data that is not signif-
icantly different from the one we observed in the TS popu-
lation. With regard to the clinical correlates of headache in
patients with TS, there was no evidence of any significant
association between the presence of headache and gender, tic
severity, or co-morbid conditions.22–24
Figure 1. PRISMA flow diagram outlining the identification, screening, assessment for eligibility and inclusion of studies in the present
review. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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The prevalence of migraine in clinical samples of
patients with TS was investigated in all the reviewed stud-
ies, with figures ranging from 12.9% to 43.3%.18–24 Studies
investigating adult patients with TS reported migraine pre-
valence figures of 12.9–39.0%,21,23,24 whereas studies
investigating paediatric patients with TS reported migraine
prevalence figures of 15.6–27.7%.18,19,21,22,24 Only one
study reported the prevalence of migraine in two control
groups consisting of paediatric patients with other neuro-
logical conditions (learning difficulties and seizure disor-
ders).18,19 The results of this study showed a significantly
higher prevalence of migraine in patients with TS com-
pared to those with learning difficulties and seizure disor-
ders (p < 0.05). The prevalence of migraine in patients with
TS could be higher than the figures reported in the general
population.25–27 Taken together, the results of our systematic
literature review are in line with previous reports of
increased prevalence of migraine in the TS population.11
With regard to the clinical correlates of migraine in TS, the
level of evidence for gender differences was overall
low.19,21,23 Common psychiatric co-morbidities such as
ADHD symptoms and obsessive–compulsive traits did not
appear to be associated with a higher prevalence of migraine
in patients with TS.21 Finally, both abnormal EEG findings20
and sleep-related behavioural symptoms19 appeared to be
more common in patients with TS and migraine.
Based on the findings of epidemiological and clinical
studies, a number of hypotheses have been suggested to
explain the increased prevalence of migraine in the TS
population. The proposed models can be grouped into three
categories: common disturbance of serotonin metabolism,
common disturbance in the extrapyramidal system and
common genetic aetiologies between migraine and TS. The
hypothesis of a shared pathophysiological basis is in line
with the available evidence of altered serotonin metabolism
in both conditions.18,21,24,28,29 Interestingly, the results of a
functional neuroimaging study showed that patients with
TS and co-morbid OCD had significantly increased levels
of dopamine alongside increased serotonin binding poten-
tial compared to patients with TS without OCD and to
healthy controls.30 These findings would be consistent with
the hypothesis that specific TS-OCD phenotypes (i.e.
patients with TS and tic-related obsessive-compulsive
behaviours) might be selectively associated with migraine.
If confirmed by further studies, this hypothesis might have
wide-ranging implications for clinical practice, as the ser-
otonergic agents used to treat OCD are also beneficial for
anxiety and affective symptoms, a common co-morbidity
of both TS and migraine.24,31–33 A shared disturbance in the
extrapyramidal system has also been proposed, mainly
based on neuroimaging findings showing the involvement
of basal ganglia–thalamocortical circuitries.34,35 Specifi-
cally, functional magnetic resonance imaging has provided
the strongest finding pointing to a role of the basal ganglia
in the pathophysiology of migraine,34 whereas both struc-
tural and functional neuroimaging studies have suggested
the involvement of the basal ganglia in the pathophysiology
of tic disorders.35 More recently, large-scale genetic studies
including genome-wide association studies have paved the
way for the study of possible shared hereditability patterns
for TS and migraine.36,37 The possibility of genetic asso-
ciations between TS and migraine would benefit from fur-
ther investigations. For example, Ganos et al. reported the
case of a male adolescent with TS, co-morbid ADHD,
obsessive–compulsive behaviour and autism spectrum dis-
order, as well as additional paroxysmal kinesigenic dyski-
nesia resulting from PRRT2 mutation misdiagnosed as
complex tics. Interestingly, the authors of this case report
were prompted to screen for mutations in the PRRT2 gene
by the significant family history of migrainous headaches,
Table 2. Quality assessment of the reviewed studies on headache in patients with TS, with individual CCAT scores.
Study
Preliminaries
(/5)
Introduction
(/5)
Design
(/5)
Sampling
(/5)
Data collection
(/5)
Ethical matters
(/5)
Results
(/5)
Discussion
(/5)
Total
(/40)
Barabas et al. /Barabas
and Matthews18,19
4 3 3 2 2 2 3 2 21
Verma et al.20 2 3 2 1 2 2 3 2 17
Kwak et al.21 5 5 2 3 4 2 4 4 29
Ghosh et al.22 5 5 4 4 4 4 4 5 35
Bertaut et al.23 2 4 2 2 3 2 2 3 20
Cavanna et al.24 4 3 2 3 3 2 3 4 24
TS: Tourette syndrome; CCAT: Crowe Critical Appraisal Tool.
Table 3. Prevalence of migraine in patients with TS.
Study
Paediatric
population
(%)
Adult
population
(%)
General
population
(%)
Barabas et al./Barabas
and Matthews18,19
27.7
Verma et al.20 43.3
Kwak et al.21 16.0 39.0 25.0
Ghosh et al.22 17.4
Bertaut et al.23 33.3
Cavanna et al.24 15.6 12.9 15.0
TS: Tourette syndrome.
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as well as the reported infantile convulsions of both the
patient and his mother.38
The three studies investigating the prevalence of
tension-type headache in samples of patients with TS found
prevalence figures ranging from 7.3% to 35.5%.22–24 Spe-
cifically, tension-type headache was diagnosed in 7.3–
28.4% of children with TS22,24 and 23.8–35.5% of adults
with TS.23,24 These preliminary findings appear to be
broadly in line with epidemiological data from the general
population,25 however, it is difficult to draw any firm con-
clusion from a small number of studies with limited sample
sizes. The results of the only study comparing children and
adults with TS24 complemented the findings of a recent
study on a large sample of 401 patients with headache,
suggesting that psychiatric symptoms and social stressors
were associated significantly more often with tension-type
headache than with migraine.39 None of the reviewed stud-
ies investigated the clinical correlates of tension-type head-
ache in TS or reported the frequency of tension-type
headache in control groups. Likewise, only one study
investigated the prevalence of other types of headache
(aura followed by non-migraine headache, headache attrib-
uted to depressive disorder, primary stabbing headache,
headache attributed to cervical myofascial pain due to
tic-related pericranial muscle overuse), reporting a figure
of 11% in a sample of 109 paediatric patients with TS.22
Clearly, further investigation is warranted in this area, with
particular attention to the characterization of the burden of
headache secondary to tics.
The present systematic literature review has limitations.
We found that there is a relative paucity of high-quality
data: a total of six independent studies met our inclusion
criteria. The reviewed studies were highly heterogeneous in
terms of diagnostic criteria, research protocols, patient
groups (some studies focused on children, whereas others
investigated adult samples). Moreover, most studies did not
report prevalence figures for headache in matched control
groups. The level of clinical heterogeneity was deemed too
high to conduct a meta-analysis on the available data. The
diagnostic criteria for both TS and headache have changed
over time, raising the possibility that the results of some of
the older studies might not be transferable or reproducible
in patients who were diagnosed more recently. Finally, the
reviewed studies recruited patients through tertiary referral
centres, where more complex and severe cases of TS tend
to be seen. Therefore, referral bias might limit the general-
izability of our findings to the wider TS population.
In summary, the first systematic literature review on the
association between headache and TS found that the pre-
valence of headache in patients with TS could be higher
than in the general population, with the most reliable data
being available for migraine. Overall, the literature on the
prevalence and characteristics of headache in TS is sparse
and highly heterogeneous. Further research on the preva-
lence and clinical correlates of migraine, tension-type
headache and other types of headache in patients with TS
across the lifespan is needed to inform clinical practice
aimed at improving health-related quality of life in patients
with tics. Specifically, if the association between TS and
migraine is confirmed by future research on larger popula-
tions, there could be relevant implications for clinical prac-
tice. For example, topiramate, a pharmacological agent
used for migraine prophylaxis, has been included in the
recently published guidelines on the treatment of tics of the
American Academy of Neurology.40–43 A better under-
standing of the relationship between migraine and tics
could assist in the characterization of TS phenotypes and
improve diagnostic and treatment strategies.
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